Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo‐Controlled, Double‐Blind Phase 2 Trial

Fibrodysplasia ossificans progressiva (FOP) is an ultra‐rare genetic disorder characterized by progressive heterotopic ossification (HO), often heralded by flare‐ups, leading to reduced movement and life expectancy. This placebo‐controlled, double‐blind trial (NCT02190747) evaluated palovarotene, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignolo, Robert J., Baujat, Geneviève, Hsiao, Edward C., Keen, Richard, Wilson, Amy, Packman, Jeff, Strahs, Andrew L., Grogan, Donna R., Kaplan, Frederick S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804935/
https://www.ncbi.nlm.nih.gov/pubmed/35854638
http://dx.doi.org/10.1002/jbmr.4655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804935/
https://www.ncbi.nlm.nih.gov/pubmed/35854638
http://dx.doi.org/10.1002/jbmr.4655

Ejemplares similares